vs

Side-by-side financial comparison of Kimbell Royalty Partners, LP (KRP) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

Kimbell Royalty Partners, LP is the larger business by last-quarter revenue ($82.5M vs $75.5M, roughly 1.1× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 23.6%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 0.1%).

Kimbell Royalty Partners, LP is a publicly traded US limited partnership focused on owning and acquiring mineral and royalty interests in oil and gas properties across key domestic producing basins including the Permian, Bakken, and Eagle Ford. Its core revenue comes from production-linked royalty payments from its diversified onshore hydrocarbon asset portfolio.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

KRP vs PBYI — Head-to-Head

Bigger by revenue
KRP
KRP
1.1× larger
KRP
$82.5M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+4.1% gap
PBYI
27.7%
23.6%
KRP
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
0.1%
KRP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KRP
KRP
PBYI
PBYI
Revenue
$82.5M
$75.5M
Net Profit
$24.8M
Gross Margin
69.3%
Operating Margin
39.6%
22.7%
Net Margin
30.1%
Revenue YoY
23.6%
27.7%
Net Profit YoY
163.2%
EPS (diluted)
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KRP
KRP
PBYI
PBYI
Q4 25
$82.5M
$75.5M
Q3 25
$80.6M
$54.5M
Q2 25
$86.5M
$52.4M
Q1 25
$84.2M
$46.0M
Q4 24
$66.7M
$59.1M
Q3 24
$83.8M
$80.5M
Q2 24
$76.6M
$47.1M
Q1 24
$82.2M
$43.8M
Net Profit
KRP
KRP
PBYI
PBYI
Q4 25
$24.8M
Q3 25
$22.3M
$8.8M
Q2 25
$26.7M
$5.9M
Q1 25
$25.9M
$3.0M
Q4 24
$-39.3M
Q3 24
$25.8M
$20.3M
Q2 24
$15.2M
$-4.5M
Q1 24
$9.3M
$-4.8M
Gross Margin
KRP
KRP
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
KRP
KRP
PBYI
PBYI
Q4 25
39.6%
22.7%
Q3 25
35.8%
17.6%
Q2 25
43.7%
12.7%
Q1 25
39.9%
8.7%
Q4 24
-58.0%
22.6%
Q3 24
40.8%
27.4%
Q2 24
31.2%
-4.6%
Q1 24
21.4%
-5.3%
Net Margin
KRP
KRP
PBYI
PBYI
Q4 25
30.1%
Q3 25
27.7%
16.2%
Q2 25
30.8%
11.2%
Q1 25
30.7%
6.5%
Q4 24
-58.8%
Q3 24
30.8%
25.2%
Q2 24
19.8%
-9.6%
Q1 24
11.4%
-11.0%
EPS (diluted)
KRP
KRP
PBYI
PBYI
Q4 25
$0.26
Q3 25
$0.17
Q2 25
$0.12
Q1 25
$0.06
Q4 24
$0.40
Q3 24
$0.41
Q2 24
$-0.09
Q1 24
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KRP
KRP
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$44.0M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$130.3M
Total Assets
$1.2B
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KRP
KRP
PBYI
PBYI
Q4 25
$44.0M
$97.5M
Q3 25
$40.0M
$94.4M
Q2 25
$34.5M
$96.0M
Q1 25
$35.6M
$93.2M
Q4 24
$34.2M
$101.0M
Q3 24
$34.7M
$96.7M
Q2 24
$30.9M
$96.8M
Q1 24
$39.7M
$107.2M
Total Debt
KRP
KRP
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
KRP
KRP
PBYI
PBYI
Q4 25
$130.3M
Q3 25
$115.3M
Q2 25
$104.7M
Q1 25
$97.1M
Q4 24
$92.1M
Q3 24
$71.1M
Q2 24
$48.5M
Q1 24
$51.0M
Total Assets
KRP
KRP
PBYI
PBYI
Q4 25
$1.2B
$216.3M
Q3 25
$1.3B
$202.9M
Q2 25
$1.3B
$194.9M
Q1 25
$1.3B
$196.2M
Q4 24
$1.1B
$213.3M
Q3 24
$1.2B
$220.7M
Q2 24
$1.2B
$205.0M
Q1 24
$1.3B
$214.1M
Debt / Equity
KRP
KRP
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KRP
KRP
PBYI
PBYI
Operating Cash FlowLast quarter
$57.2M
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
2.31×
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KRP
KRP
PBYI
PBYI
Q4 25
$57.2M
$14.4M
Q3 25
$62.8M
$9.7M
Q2 25
$72.3M
$14.1M
Q1 25
$54.2M
$3.6M
Q4 24
$56.6M
$15.6M
Q3 24
$62.4M
$11.0M
Q2 24
$62.9M
$1.0M
Q1 24
$69.0M
$11.2M
Free Cash Flow
KRP
KRP
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
Q3 24
$11.0M
Q2 24
$1.0M
Q1 24
FCF Margin
KRP
KRP
PBYI
PBYI
Q4 25
19.1%
Q3 25
17.7%
Q2 25
26.8%
Q1 25
7.7%
Q4 24
26.4%
Q3 24
13.7%
Q2 24
2.1%
Q1 24
Capex Intensity
KRP
KRP
PBYI
PBYI
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
KRP
KRP
PBYI
PBYI
Q4 25
2.31×
Q3 25
2.81×
1.10×
Q2 25
2.71×
2.41×
Q1 25
2.09×
1.21×
Q4 24
Q3 24
2.42×
0.54×
Q2 24
4.14×
Q1 24
7.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KRP
KRP

Oil And Condensate$45.9M56%
Natural Gas Midstream$19.5M24%
NGL Revenue$10.6M13%
Other$6.4M8%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons